Epidemiology of Hepatocellular Carcinoma

Surgical Oncology Clinics of North America

Volumn 24, Issue 1, 2015, Pages 1-17

  Lafaro, Kelly J ^a   Demirjian, Aram N ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aflatoxin; Chronic liver disease; Cirrhosis; Hepatitis b; Hepatitis c; Hepatocellular carcinoma; Incidence; Risk factors

Indexed keywords

AFLATOXIN; ALCOHOL; ANTIVIRUS AGENT; HEPATITIS B VACCINE; INSULIN; INTERLEUKIN 6; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AFRICA; AGE; AGED; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOL WITHDRAWAL; ASIA; ASPERGILLUS FLAVUS; ASPERGILLUS PARASITICUS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SCREENING; CHILD; CHRONIC LIVER DISEASE; EARLY DIAGNOSIS; EUROPE; FATTY LIVER; FOOD CONTAMINATION; GEOGRAPHY; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; UNITED STATES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84921760685     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.09.001     Document Type: Review

References (100)

1. Ferlay J., Shin H., Bray F., et al. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 2010, [Internet], International Agency for Research on Cancer, Lyon (France).
2. Shariff M., Cox I., Gomaa A., et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009, 3(4):353-367.
3. Custer B., Sullivan S., Hazlet T., et al. Global epidemiology of hepatitis B virus. JClin Gastroenterol 2004, 38(10):S158-S168.
4. Chang M., You S., Chen C., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. JNatl Cancer Inst 2009, 101(19):1348-1355.
5. El-Serag H., Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
6. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62(S1):8-17.
7. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5):35-S50.
8. Pellicelli A., Romano M., Stroffolini T., et al. HCV genotype 1a shows a better virologic response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 2012, 12(162):1-7.
9. Kew M. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol 2013, 12(2):173-182.
10. Altekruse S., McGlynn K., Reichman M. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27(9):1485-1491.
11. Mittal S., El-Serag H. Epidemiology of hepatocellular carcinoma: consider the population. JClin Gastroenterol 2013, 47:S2-S6.
12. Bosch F., Ribes J., Cléries R., et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005, 9(2):191-211.
13. Branda M., Wands J. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006, 43(5):891-902.
14. Tsai W., Chung R. Viral hepatocarcinogenesis. Oncogene 2010, 29(16):2309-2324.
15. Beasley R., Hwang L., Lin C., et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981, 2(8256):1129-1133.
16. Tabor E. Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001, 33(2):115-117.
17. McMahon B. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009, 3(2):334-342.
18. Chan H., Hui A., Wong M., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004, 53(10):1494-1498.
19. Kao J., Chen P., Lai M., et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118(3):554-559.
20. Lee C., Chen C., Lu S., et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003, 38(1):95-101.
21. Tangkijvanich P., Mahachai V., Komolmit P., et al. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. World J Gastroenterol 2005, 11(15):2238-2243.
22. Chisari F. Rous-Whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156(4):1117-1132.
23. Dandri M., Burda M., Bürkle A., et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002, 35(1):217-223.
24. Bonilla Guerrero R., Roberts L. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. JHepatol 2005, 42(5):760-777.
25. Ferber M., Montoya D., Yu C., et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22(24):3813-3820.
26. Wu B., Li C., Chen H., et al. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 2006, 340(3):916-928.
27. Yang H., Lu S., Liaw Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. NEngl J Med 2002, 347(3):168-174.
28. Yuen M., Tanaka Y., Fong D., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. JHepatol 2009, 10(1):80-88.
29. Chen C., Yang H., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
30. Simonietti R., Camma C., Fiorello F., et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991, 36:962-972.
31. Tiribelli C., Melato M., Croce L., et al. Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities in the world-Trieste, Italy and China, Japan. Hepatology 1989, 10:998-1002.
32. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
33. Benvegnu L., Gios M., Boccato S., et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-749.
34. Tsai J., Jeng J., Ho M., et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997, 76:968-974.
35. McGlynn K., London W. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011, 15(2):223-243.
36. Choo Q., Kuo G., Weiner A., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
37. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155(4):323-331.
38. Zaltron S., Spinetti A., Biasi L., et al. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012, 12(Suppl 2):S2-S7.
39. Freeman A., Dore G., Law M., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34(4):809-816.
40. Seeff L. Natural history of chronic hepatitis C. Hepatology 2002, 36(5 Suppl 1):S35-S46.
41. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349(9055):825-832.
42. Shindo M., Arai K., Sokawa Y., et al. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995, 22(2):418-425.
43. Mathurin P., Moussalli J., Cadranel J., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998, 27(3):868-872.
44. Backus L., Boothroyd D., Phillips B., et al. Asustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9(6):509-516.
45. Singal A., Volk M., Jensen D., et al. Asustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8(3):280-288.
46. Morgan R., Baack B., Smith B., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158(5 Pt 1):329-337.
47. Zhu H., Jia Z., Misra H., et al. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. JDig Dis 2012, 13(3):133-142.
48. IARC Working Group Alcohol drinking. IARC Monogr Eval Carcinog Risks Hum 1988, 44:1-378.
49. Yuan J., Govindarajan S., Arakawa K., et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer 2004, 101(5):1009-1017.
50. Grewal P., Viswanathen V. Liver cancer and alcohol. Clin Liver Dis 2012, 16(4):839-850.
51. Marrero J., Fontana R., Fu S., et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. JHepatol 2005, 42(2):218-224.
52. Trichopoulos D., Bamia C., Lagiou P., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. JNatl Cancer Inst 2011, 103(22):1686-1695.
53. Corrao G., Bagnardi V., Zambon A., et al. Ameta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004, 38(5):613-619.
54. Heckley G., Jarl J., Asamoah B., et al. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011, 11(446):1-10.
55. Boveris A., Fraga C., Varsavsky A., et al. Increased chemiluminescence and superoxide production in the liver of chronically ethanol-treated rats. Arch Biochem Biophys 1983, 227(2):534-541.
56. Kukiełka E., Dicker E., Cederbaum A. Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch Biochem Biophys 1994, 309(2):377-386.
57. Kuper H., Tzonou A., Kaklamani E., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85(4):498-502.
58. Berman K., Tandra S., Vuppalanchi R., et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol 2011, 106(5):899-906.
59. Kubo S., Kinoshita H., Hirohashi K., et al. High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus. Surgery 1997, 121(4):425-429.
60. IARC Working Group Aflatoxins. IARC Monogr Eval Carcinog Risks Hum 2002, 82:171-300.
61. Liu Y., Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010, 118(6):818-824.
62. Hsu I., Metcalf R., Sun T., et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991, 350(6317):427-428.
63. Bressac B., Kew M., Wands J., et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350(6317):429-431.
64. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338(8779):1356-1359.
65. Qian G., Ross R., Yu M., et al. Afollow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994, 3(1):3-10.
66. Neuschwander-Tetri B., Caldwell S. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37(5):1202-1219.
67. Nishikawa H., Osaki Y. Non-B, non-C hepatocellular carcinoma (review). Int J Oncol 2013, 43(5):1333-1342.
68. Tokushige K., Hashimoto E., Horie Y., et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. JGastroenterol 2011, 46(10):1230-1237.
69. Torres D., Harrison S. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012, 32(1):30-38.
70. Welzel T., Graubard B., Zeuzem S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54(2):463-471.
71. Wolk A., Gridley G., Svensson M., et al. Aprospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12(1):13-21.
72. Attner B., Landin-Olsson M., Lithman T., et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 2012, 23(5):769-777.
73. Hashimoto E., Yatsuji S., Tobari M., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. JGastroenterol 2009, 44(Suppl 19):89-95.
74. Ascha M., Hanouneh I., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51(6):1972-1978.
75. Calle E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. NEngl J Med 2003, 348(17):1625-1638.
76. Shimizu M., Tanaka T., Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 2013, 35(2):191-202.
77. Tung H., Wang J., Tseng P., et al. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol 2010, 105(3):624-631.
78. El-Serag H., Tran T., Everhart J. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
79. Hassan M., Curley S., Li D., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116(8):1938-1946.
80. Zheng Z., Zhang C., Yan J., et al. Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area. PLoS One 2013, 8(12):e84776.
81. Polesel J., Zucchetto A., Montella M., et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009, 20(2):353-357.
82. Wang C., Wang X., Gong G., et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012, 130(7):1639-1648.
83. Hassan M., Kaseb A. Hepatocellular carcinoma. Targeted therapy and multidisciplinary care 2011, vol. 1:1-19. Springer, New York (NY).
84. Harrison S. Liver disease in patients with diabetes mellitus. JClin Gastroenterol 2006, 40(1):68-76.
85. Alexia C., Fallot G., Lasfer M., et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004, 68(6):1003-1015.
86. Hu W., Feng Z., Eveleigh J., et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002, 23(11):1781-1789.
87. Donadon V., Balbi M., Dal Mas M., et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010, 30(5):750-758.
88. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125(6):1733-1741.
89. Yang Q., McDonnell S., Khoury M., et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998, 129(11):946-953.
90. Lata J. Chronic liver diseases as liver tumor precursors. Dig Dis 2010, 28(4-5):596-599.
91. Mizoue T., Tokui N., Nishisaka K., et al. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol 2000, 29(2):232-237.
92. Yun Y., Jung K., Bae J., et al. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. Cancer Detect Prev 2005, 29(1):15-24.
93. Zhu K., Moriarty C., Caplan L., et al. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control 2007, 18(3):315-321.
94. Jee S., Ohrr H., Sull J., et al. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. JNatl Cancer Inst 2004, 96(24):1851-1856.
95. Sun C., Wu D., Lin C., et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003, 157(8):674-682.
96. Zaman S., Melia W., Johnson R., et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985, 1(8442):1357-1360.
97. Yuan J., Ross R., Stanczyk F., et al. Acohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 1995, 63(4):491-493.
98. Naugler W., Sakurai T., Kim S., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317(5834):121-124.
99. Davis G., Albright J., Cook S., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9(4):331-338.
100. Sandler R., Everhart J., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122(5):1500-1511.